Hydrogen Sulfide as Prognostic Factor (H2S-1)
|ClinicalTrials.gov Identifier: NCT01088490|
Recruitment Status : Completed
First Posted : March 17, 2010
Last Update Posted : December 5, 2014
|Condition or disease|
Hide Detailed Description
Hydrogen sulfide (H2S), better known as a poisonous gas, has lately emerging as a third gaseous transmitter in mammals, next to nitric oxide (NO) and carbon monoxide (CO). H2S is present in most human tissues in concentrations up to 50 μM. Most of it is synthesized in brain, cardiovascular system, kidneys and liver. In human tissues H2S is synthesized from L-cysteine by two enzymes cystathionine-γ-lyase and cystathionine-β-synthase. H2S works by stimulating ATP sensitive potassium channels and is involved in regulation of vascular tone, myocardial contractility, insulin secretion and neurotransmission. In numerous animal models, H2S deficiency was shown in arterial and pulmonary arterial hypertension, Alzheimer's disease and liver cirrhosis. Increased production and higher serum concentrations were shown in inflammatory diseases, septic shock and stroke.
Most of studies so far were conducted on animals and already show some therapeutic potentials. In available literature there have been no studies in humans focused on H2S concentrations in critically ill and its prognostic value.
Hypothesis We will test the hypothesis that higher serum H2S concentrations on admission to ICU are linked with higher mortality in patients with shock of any reason.
Serum H2S concentrations are related to treatment support with vaso-active drugs (noradrenalin, epinephrine).
Material and methods In the study we will include adult patients admitted to medical ICU due to shock of any reason. Shock is defined as systemic arterial pressure lower than 90mmHg or drop for systemic arterial pressure at least 40mmHg for 15minutes or more with elevation of serum lactate value.
Patients will be included on basis of clinical appearance of shock - hypotension or need for vasopressors, brady- or tachycardia, signs of peripheral hypo perfusion, oliguria and changes in mental status.
Exclusion criteria: patient younger then 18years and patients not in shock
From blood samples drawn on admission to ICU we will measure H2S concentration. H2S concentration will be measured spectrophotometrically5 as first described in 19496 and further refined in 19657. Spectrophotometrical determination of H2S concentration in tissue and plasma was previously used by many researchers.3,8-11 Blood samples will be centrifuged as quickly after collection to obtain plasma. 200 μL of plasma will be mixed with pre-prepared solution of 100 μL 10% (wt/vol) trichloroacetic acid and 60 μL 1% (wt/vol) zinc acetate, to trap dissolved H2S. The mixture will be frozen at 20 C until further analysis.
After sufficient number of samples will be obtained, we will measure H2S concentration in series. 40µL 20 µM N,N-dimethyl-p-phenylenediamine sulfate in 7,2 M HCl and 40µL 30 µM FeCl3 v 1,2 M HCl will be added to unfrozen samples. After 10-20 min incubation at room temperature final mixtures will be centrifuged at 9000 rpm for 5 minutes to remove precipitate. After centrifugation absorption at 670 nm will be measured with spectrophotometer. All analysis will be done in duplicates.
Calibration curve of absorbance versus sulfide concentration will be obtained from known concentration of Na2S (0,699 µM - 69,93 µM) and concentrations of H2S in plasma calculated.
Impact of plasma H2S concentration on admission to ICU on ICU mortality will be observed trough nonparametric statistical analysis.
Expectations We hypothesize that higher serum H2S concentrations on admission to ICU in patients with shock of any cause are indicators of severity of shock and cardiovascular deterioration, related to treatment support with vaso-active drugs (noradrenalin, epinephrine). Thus higher serum H2S concentrations are expected to be better prognostic factor of ICU mortality in patients with shock than currently established lactic acid.
|Study Type :||Observational|
|Actual Enrollment :||50 participants|
|Official Title:||Hydrogen Sulfide as Prognostic Factor|
|Study Start Date :||January 2010|
|Actual Primary Completion Date :||January 2012|
|Actual Study Completion Date :||January 2014|
Critically ill patients admitted to ICU
- Prognostic value of H2S [ Time Frame: In hospital; ICU mortality 30days ]
relationship between H2S and mortality of patients during intensive care treatment,
comparison of H2S and lactate prognostic value
- Correlation of H2S with vasopressor requirements [ Time Frame: ICU treatmennt 30days ]relationship between H2S and dose of vasopressors (noradrenaline, epinephrine) used
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01088490
|University Medical Center|
|Ljubljana, Slovenia, 1000|
|Principal Investigator:||Matej Podbregar, MD PhD||University Medical Centre Ljubljana|